Avadel Pharmaceuticals (AVDL) Other Non-Current Liabilities (2016 - 2022)
Historic Other Non-Current Liabilities for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to $5.7 million.
- Avadel Pharmaceuticals' Other Non-Current Liabilities rose 4321.08% to $5.7 million in Q3 2022 from the same period last year, while for Sep 2022 it was $5.7 million, marking a year-over-year increase of 4321.08%. This contributed to the annual value of $3.9 million for FY2021, which is 700.38% down from last year.
- As of Q3 2022, Avadel Pharmaceuticals' Other Non-Current Liabilities stood at $5.7 million, which was up 4321.08% from $5.7 million recorded in Q2 2022.
- In the past 5 years, Avadel Pharmaceuticals' Other Non-Current Liabilities registered a high of $14.3 million during Q1 2018, and its lowest value of $3.8 million during Q1 2022.
- Moreover, its 5-year median value for Other Non-Current Liabilities was $5.7 million (2022), whereas its average is $8.2 million.
- In the last 5 years, Avadel Pharmaceuticals' Other Non-Current Liabilities surged by 15969.39% in 2018 and then plummeted by 6465.79% in 2020.
- Quarter analysis of 5 years shows Avadel Pharmaceuticals' Other Non-Current Liabilities stood at $14.0 million in 2018, then crashed by 36.63% to $8.9 million in 2019, then tumbled by 52.53% to $4.2 million in 2020, then fell by 7.0% to $3.9 million in 2021, then surged by 46.21% to $5.7 million in 2022.
- Its last three reported values are $5.7 million in Q3 2022, $5.7 million for Q2 2022, and $3.8 million during Q1 2022.